European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

BEERSE, BELGIUM, May 24, 2021 – Janssen, the Pharmaceutical Companies of Johnson &Johnson, announced today that the European Commission (EC) has approved PONVORY (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[4] “Relapsing multiple sclerosis is an unpredictable and complex disease that can present very differently from individual to individual, placing a heavy burden on the patient and their loved ones,” said Professor Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Professor of Neurology at Queen Mary University of London. “I welcome the European Commission’s approval of ponesimod as an additional treatment option for those living with relapsing multiple sclerosis - it will provide patients with additional choice when making decisions about their treatment.” The EC approval of ponesimod is based on data from the Phase 3 OPTIMUM trial, a multicentre, randomised, double-blind, parallel-group, active-controlled superiority study of 1,133 adult patients (aged 18-55 years) in 28 countries.1 The trial was designed to evaluate the efficacy and safety of once daily oral ponesimod (20mg) vs. once-daily teriflunomide (14mg), an approved and widely-used first-line oral treatment, in adult patients with RMS.1 The large, Phase 3 study showed superior efficacy of ponesimod 20mg on the primary endpoint, annualised relapse rate (ARR), ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

ConclusionThe results of this 10-year longitudinal study imply a positive correlation between long-standing hypertension and the progression of DWMLs.
Source: Neuroradiology - Category: Radiology Source Type: research
This study set out to assess for any such associations.Materials and methodsA retrospective review was completed of consecutive patients that had CTA neck imaging prior to CEA. Body mass index (BMI), tobacco and/or alcohol use, and history of diabetes and/or hypertension were collected from patients ’ medical records. Lab values were dichotomized based on values: total cholesterol
Source: Neuroradiology - Category: Radiology Source Type: research
Abstract: Immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue has been proposed as a potential tool in the diagnosis of autoimmune bullous diseases (AIBDs) in lieu of standard direct immunofluorescence (DIF) microscopy. To comprehensively determine the diagnostic accuracy of immunoglobulin and complement IHC for diagnosis of AIBDs, we conducted a systematic review and multivariate Bayesian model-based meta-analysis of the literature. Quality and heterogeneity assessment of studies was performed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist and the I2 index, respecti...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Review Article Source Type: research
In conclusion, the current study shows that C4d is a more sensitive but not a 100% specific marker of BP. We conclude that C4d by DIF could be an interesting diagnostic adjunct for BP, particularly in IgG−/C3c− double negative cases.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Brief Report Source Type: research
Abstract: Human papillomavirus (HPV) is a leading cause of cancer. Increasing HPV vaccination recommendations by primary care providers to patients decreases the burden of this viral infection. Providers need to be educated about this condition and the available options for immunization to feel confident in making strong recommendations and thereby increase HPV immunization rates.
Source: The Nurse Practitioner - Category: Nursing Tags: Feature Source Type: research
Abstract: Patients who present to an outpatient office with hypertensive urgency—or severely elevated BP without evidence of acute target organ damage—can be safely treated in the ambulatory setting by initiating or reestablishing long-acting oral antihypertensive medications, addressing medication nonadherence, and reviewing precipitating factors.
Source: The Nurse Practitioner - Category: Nursing Tags: Feature: HYPERTENSION Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
A federal appeals court has issued a temporary injunction against a Covid-19 vaccine mandate for New York City educators set to go into...
Source: Reuters: Health - Category: Consumer Health News Source Type: news
HIGH blood pressure is often known as the "silent" killer. Ironically, silence could help lower blood pressure - research shows even just two minutes of silence could have a positive effect on a high reading.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
A dry cough, sniffles and a headache. Burning muscle pain. And everything you eat tastes like dust. It's a list of symptoms the British public have become all too familiar with - classic Covid. Or is it?
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: African Health | Allergy & Immunology | Alopecia | Autoimmune Disease | Belgium Health | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Common Cold | Disability | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Headache | Health Management | Heart | Hypertension | Iceland Health | Infectious Diseases | Learning | Legislation | Liechtenstein Health | Middle East Health | Migraine | Multiple Sclerosis | Neurology | Neuroscience | Neurosurgery | Norway Health | Pharmaceuticals | Pulmonary Hypertension | Respiratory Medicine | Science | Statistics | Study | Universities & Medical Training | Vaccines | Vertigo